Brian Orr, MD
Gynecologic Oncology · Charleston, SCNPI 1437478146
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $1,925 of the $2,689 with a category attached, or 71.6%. Seagen Inc. accounts for 71.6% of it on its own, with 7 other manufacturers making up the rest. Reporting peaked in 2021 at $2,019 and has fallen 98.7% since, to $26 in 2025.
Across 16 payments — averaging $168.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Seagen Inc.$2K
- Clovis Oncology, Inc.$240
- AbbVie$126
- Tesaro, Inc.$125
- Myriad Genetic Laboratories, Inc.$116
- Sumitomo Pharma America, Inc.$71
- plus $86 from 2 others
Across 77 payments — averaging $1440.93 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Clovis Oncology, Inc.$58K
- Seagen Inc.$31K
- Chugai Pharmaceutical Co., Ltd.$18K
- Daiichi Sankyo Inc.$2K
- Merck$483
- Pharmaand GmbH$428
What the payments were for
- Consulting fees$1,92572%
- Food & beverage$72027%
- Education$442%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Seagen Inc. | 1 | $1,925 |
| Clovis Oncology, Inc. | 3 | $240 |
| AbbVie | 1 | $126 |
| Tesaro, Inc. | 1 | $125 |
| Myriad Genetic Laboratories, Inc. | 2 | $116 |
| Sumitomo Pharma America, Inc. | 3 | $71 |
| Merck | 4 | $59 |
| Johnson & Johnson | 1 | $27 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few gynecologic oncology providers in South Carolinato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LynparzaOlaparib | 13 | $180,867 |
| EliquisApixaban | 34 | $20,963 |
| Letrozole | 59 | $1,240 |
| Estradiol | 20 | $646 |
| Ondansetron Hcl | 30 | $228 |
| Oxycodone Hcl | 21 | $196 |
| Dexamethasone | 11 | $165 |
| Prochlorperazine Maleate | 13 | $121 |
| Amlodipine Besylate | 15 | $107 |
| Tramadol Hcl | 32 | $49 |
Paid to pharmacies, not to this prescriber.
Other gynecologic oncology in Charleston
- Whitney GraybillCharleston$81K
- Courtney BaileyCharleston$5K
- Jonathan FooteCharleston$3K
- Catherine WatsonCharleston$3K
- Ward KatsanisCharleston$1K
- Thomas JenningsCharleston$1K
- David MysonaCharleston$73
- William MerrittColumbia$9K
- Mark MillerWest Columbia$8K
- James WilliamsColumbia$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.